MECHELEN, BELGIUM--(Marketwire - Nov 11, 2012) - Galapagos NV (EURONEXT BRUSSELS: GLPG)
today that the single center Proof of Concept results from 2011 in
arthritis with selective JAK1 inhibitor GLPG0634 will be presented
American College of Rheumatology (ACR) Annual meeting in Washington,
Furthermore, the Company will present a poster on Phase I results
excellent safety at higher doses of GLPG0634, showing that no maximum
dose was reached.
The oral presentation will form part of the session entitled:
Arthritis Treatment - Small Molecules, Biologics and Gene Therapy:
Efficacy of Janus Activated-Kinase (JAK) Inhibitors." The presentation
highlight the differentiated safety and efficacy profile of GLPG0634
rheumatoid arthritis patients treated for 28 days in a single center
Selective JAK1 Inhibition in the Treatment of Rheumatoid Arthritis:
Concept with GLPG0634 (13-Nov, 3:30 PM, Ballroom C, Abstract #2489)
The poster data demonstrate that GLPG0634 shows selective JAK1 inhibition,
safety and maintained JAK1-related biomarker response for up to 10 days
dosing of 300 mg and 450 mg in healthy volunteers. Biomarker data also
that JAK1 is inhibited throughout the day for once-daily dosing of
healthy volunteers. As 450 mg is the highest dose ever investigated, no
tolerated dose for GLPG0634 was attained:
Once Daily Higher Dose Regimens of GLPG0634 in Healthy Volunteers Are
Provide Continuous Inhibition of JAK1 but not JAK2 (12-Nov, 9:00 AM -
Poster Hall B, Abstract #1331)
The full abstracts can be accessed through the ACR website. The poster
available in PDF format on Galapagos' website: www.glpg.com.
About candidate drug GLPG0634
GLPG0634 is an orally-available, novel Janus kinase (JAK) inhibitor with
selectivity for JAK1 currently in Phase II and being developed by
JAKs are critical components of signaling mechanisms utilized by a number
cytokines and growth factors, including those that are elevated in
arthritis patients. JAK inhibitors have shown long-term efficacy in
arthritis trials with an early onset of action. Galapagos aims to
GLPG0634 from other JAK inhibitors in development by specifically targeting
JAK1, a strategy which could result in a cleaner safety profile.
Galapagos (EURONEXT BRUSSELS: GLPG) (PINKSHEETS: GLPYY) is a
mid-size clinical stage
biotechnology company specialized in the discovery and development of
molecule and antibody therapies with novel modes-of-action. The
progressing its JAK1 inhibitor GLPG0634, as well as one of the largest
in biotech, with four programs in development and over 30 discovery
The Galapagos Group has over 800 employees and operates facilities
countries, with global headquarters in Mechelen, Belgium. More
This release may contain forward-looking statements, including,
limitation, statements containing the words "believes,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions,
achievements expressed or implied by such forward-looking statements.
these uncertainties, the reader is advised not to place any undue
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly
obligation to update any such forward-looking statements in this
reflect any change in its expectations with regard thereto or any
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE